Chinese biotechnology start-up AnHeart Therapeutics announced on Wednesday that it has raised approximately RMB100 million (US$14.54 million) in a series A round of financing from the country’s venture capital firm Decheng Capital. Founded in November 2018, AnHeart Therapeutics is a clinical-stage biopharmaceutical company focused on the development, commercialization, and acquisition of innovative medicines that can […]

Chinese VC Firm Decheng Capital Backs $14M Series A Round Of Biotech Start-Up comes originally from China Money Network. All Rights Reserved.